Introduction {#s1}
============

The vertebrate CPE-binding protein (CPEB) family of RNA-binding proteins is composed of four members, with CPEBs 2--4 being more closely related to each other than to CPEB1 (reviewed in refs. \[[@bib16]; [@bib21]\]). All four CPEBs share similar C-terminal RNA-binding domains, composed of two RNA recognition motifs (RRMs) in tandem, followed by a ZZ domain, which is a zinc-binding domain with a cross-braced zinc binding topology. Consequently, the different CPEBs recognize similar *cis*-acting cytoplasmic polyadenylation elements (CPEs) on target mRNAs ([@bib1]; [@bib20]; [@bib31]; [@bib34]; [@bib35]; [@bib38]). Although up to 20--30% of vertebrate genes are regulated by CPEs, they are not all activated simultaneously. Rather, the CPEs define a combinatorial code, based on their number and distance to the polyadenylation signal (PAS), as well as the presence of additional *cis*-acting elements, to determine the transcript-specific spatiotemporal translation pattern ([@bib4]; [@bib15]; [@bib28]; [@bib39]). The CPE-mediated spatiotemporal patterns of translational control are further determined by the differential regulation of the CPEBs. All four CPEBs have dual functions as translational repressors and translational activators (by promoting cytoplasmic polyadenylation). This duality is differentially regulated for individual CPEB family members through post-translational modifications. Thus, it is plausible that distinct regulatory pathways provide a platform to support translational activation by cytoplasmic polyadenylation in different biological scenarios. At least for CPEB1 and CPEB3, the regulatory elements are localized in the N-terminal domain (NTD), which is highly variable both in length and composition across various CPEB orthologs and paralogs ([@bib44]). Notably, CPEBs' NTDs contain intrinsically disordered regions (IDR), which are more extended in CPEB2, CPEB3 and CPEB4. IDR are particularly prevalent in RNA-binding proteins and, over the last years, have been shown to drive the formation of dynamic membraneless organelles (such as P-bodies, germ granules, stress granules and the nucleolus) through phase separation ([@bib7], [@bib8]; [@bib25]; [@bib9]; [@bib26]; [@bib37]; [@bib33]; [@bib32]).

For CPEB3 and its *Drosophila* and *Aplysia* orthologs, Orb2 and ApCPEB respectively, the switch from repressor to activator has been proposed to be regulated through a prion-like multimerization mechanism in neurons ([@bib24]; [@bib27]; [@bib40]). These CPEBs contain polyglutamine stretches in their NTDs that promote the formation of amyloid-like fibrils. CPEB3 multimerization is regulated by non-proteolytic mono-ubiquitination and SUMOylation, and the aggregated form promotes the polyadenylation and translational activation of its target mRNAs ([@bib13]; [@bib22]; [@bib38]).

CPEB1 is regulated by two sequential phosphorylation events during the first meiotic division. In prophase I (PI)--arrested *Xenopus* oocytes, unphosphorylated CPEB1 recruits the deadenylase poly(A)-specific ribonuclease (PARN) to inhibit translation ([@bib23]). Upon progesterone stimulation, Aurora kinase A (AurKA) phosphorylates CPEB1 at S174, which remodels CPEB1-mRNP from a repressor to an activator complex, thereby inducing the early wave of cytoplasmic polyadenylation required for the activation of cyclin-dependent kinase 1 (Cdk1) and MI entry ([@bib3]; [@bib29], [@bib30]; [@bib39]). Once the oocytes reach metaphase I (MI), Cdk1 and Polo-like kinase 1 (Plk1) target CPEB1 to ubiquitin-mediated degradation, and this is required to activate the second or 'late' wave of polyadenylation and the MI--MII transition ([@bib28]; [@bib39]; [@bib41]). In the second meiotic division, a third or 'late-late' wave of polyadenylation is supported by CPEB4, which is synthesized during the early and CPEB1-mediated wave of polyadenylation ([@bib4]; [@bib20]). Thus, CPEB4 is only present in the second meiotic division. However, the synthesis of CPEB4 alone is not sufficient to promote cytoplasmic polyadenylation, and progesterone stimulation is still required ([@bib34]). These observations suggest that CPEB4 is not constitutively active but has to be post-translationally modified to become active. Unlike CPEB1, CPEB4 does not harbour a consensus AurKA phosphorylation site; therefore, it is most likely activated by distinct phosphorylation event(s) during later meiotic phases. Hence, we sought to elucidate the post-translational regulation of CPEB4 that is required for it to support cytoplasmic polyadenylation after CPEB1 has been degraded and to drive the second meiotic division. Unravelling how CPEB4 activity is regulated will contribute to the overall understanding of the CPEB network in mRNA translational control and to defining the phase-specific contributions of individual CPEBs to the unidirectional progression through meiotic and mitotic cell cycle ([@bib18]; [@bib20]).

Here we show that CPEB4 activity is regulated by ERK2- and Cdk1-mediated phosphorylation at 12 residues surrounding two intrinsically disordered regions (IDRs) in CPEB4's NTD. These phosphorylation events additively activate CPEB4 for cytoplasmic polyadenylation and, consequently, are required for proper meiotic progression. Furthermore, CPEB4 hyperphosphorylation keeps CPEB4 in a monomeric and active state. In contrast, unphosphorylated CPEB4 sequesters CPE-containing mRNAs into inactive, liquid-like droplets formed through intermolecular interactions between residues in CPEB4's NTD. These results illustrate how phase transitions can be regulated through post-translational modifications and explain how CPEB-specific mechanisms of regulation sustain and coordinate cytoplasmic polyadenylation during cell cycle progression, adapting to the cell signalling transduction pathways activated at each cell cycle phase.

Results {#s2}
=======

xCPEB4 is phosphorylated in 12 residues by ERK2 and Cdk1 {#s2-1}
--------------------------------------------------------

To address whether *Xenopus* CPEB4 (xCPEB4) is post-translationally modified by phosphorylation or by alternative modifications in a cell cycle--dependent manner, we first microinjected mRNA coding for HA-tagged xCPEB4 in stage VI--arrested oocytes and then triggered meiotic resumption with progesterone. Progression from the PI arrest (stage VI) to MI (shown as germinal vesicle breakdown, GVBD) caused a change in mobility, which was maintained through anaphase/interkinesis (GVBD + 1 hr) and in the MII arrest (MII). This mobility shift was abrogated by treatment with lambda-phosphatase, indicating that xCPEB4 was phosphorylated in response to progesterone ([Figure 1B](#fig1){ref-type="fig"}). To further define the xCPEB4 region(s) phosphorylated in a cell-specific manner, we subdivided xCPEB4 into four fragments, with three (1--3) comprising sections of its NTD and the fourth comprising the whole RNA-binding domain (RBD) ([Figure 1A](#fig1){ref-type="fig"}). *In vitro* phosphorylation of full-length (FL) xCPEB4 or the four xCPEB4 fragments with extracts from MII oocytes indicated that multiple residues were targeted in fragments 1--3 but none, or only very few, in the RBD fragment ([Figure 1C](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). To further define the phase specificity of the phosphorylation events, we tested each fragment for *in vitro* phosphorylation with extracts from oocytes collected either prior to progesterone stimulation (PI arrested; VI) or at various times after GBVD, corresponding to MI (GBVD and +30 min), anaphase/interkinesis (+60 min and +90 min) and MII-arrest (+120 min and +150 min) ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Neither FL xCPEB4 nor any of the fragments were phosphorylated by PI-arrested oocyte extracts. FL xCPEB4 and fragment 1 were phosphorylated in MI and remained phosphorylated throughout the subsequent cell cycle phases. In contrast, fragment 3 was differentially phosphorylated by the extracts from the distinct meiotic phases, following the characteristic kinetics of Cdk1 ([@bib28]), as shown by the phosphorylation of histone H1. The phosphorylation kinetics of fragment 2 was intermediate between fragments 1 and 3. In sum, these results indicate that xCPEB4 is phosphorylated at multiple residues in its NTD by distinct kinases that are differentially active during meiotic progression, one of which is most likely Cdk1.10.7554/eLife.19298.002Figure 1.xCPEB4 NTD is phosphorylated in response to progesterone.(**A**) Schematic representation of xCPEB4 protein. The four protein fragments generated are: 1, from amino acid (aa) 1 to 202; 2, from aa 203 to 290; 3, from aa 291 to 409; and RBD, from aa 402 to 702. RRMs are shown in blue and the ZZ domain, in grey. (**B**) Lambda-phosphatase assay (λ) of oocytes overexpressing HA-xCPEB4 collected at the indicated times (VI, prophase I; GVBD, germinal vesicle breakdown; MII, metaphase II). Western blots with anti-HA antibody and anti-tubulin (as a loading control) are shown. C, control, corresponds to non-injected oocytes. (**C**) *In vitro* kinase assay of recombinant xCPEB4, full-length (FL) or the fragments 1, 2, 3 or RBD, using metaphase II oocyte extracts as the source of kinases (autoradiography, ^32^P). (**D**) Time course of the *in vitro* kinase assay of recombinant xCPEB4, FL or fragments (1, 2 and 3), using oocyte extracts collected at the indicated times (autoradiography, ^32^P). Histone H1 phosphorylation was used to follow Cdk1 activity. Three independent biological replicates were performed, with equivalent findings each time. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.002](10.7554/eLife.19298.002)10.7554/eLife.19298.003Figure 1---figure supplement 1.Loading controls for *in vitro* kinase assays.(**A**) Loading control for [Figure 1C](#fig1){ref-type="fig"}. Upper panel corresponds to the Coomassie blue--stained gel (CBB with extract). In the lower panel, equivalent protein amounts used in the assay were loaded for a clearer loading control (CBB without extract). (**B**) Loading control for [Figure 1D](#fig1){ref-type="fig"}, in a Coomassie blue--stained gel.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.003](10.7554/eLife.19298.003)

To further determine the kinases targeting xCPEB4, we performed *in vitro* phosphorylation assays on FL-xCPEB4 and on fragments 1--3 using MII oocyte extracts as the kinase source, in the presence or absence of inhibitors of Cdks (roscovitine), p90Rsk (SL0101), Plk1 (BI-2536), MEK (U0126) or ERK (FR180204) ([Figure 2A,B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). All these kinases are active in MII ([@bib43]) (for Cdks and ERK, Cdk1 and ERK2 are the active kinases in MI and MII). Phosphorylation of the FL protein was strongly inhibited by FR180204, partially inhibited by roscovitine and BI-2536, and unaffected by SL0101 and U0126, suggesting that ERK2, Cdk1 and Plk1, but not MEK or p90Rsk, target xCPEB4. Phosphorylation of fragments 1 and 2 was specifically inhibited by FR180204, whereas that of fragment 3 was more sensitive to roscovitine, suggesting that ERK2 and Cdk1 target specific regions of the xCPEB4 NTD. We further confirmed the role of ERK2 and Cdk1 in xCPEB4 phosphorylation by immunodepleting the kinases from phase-specific meiotic extracts, with the subsequent reduction of xCPEB4 phosphorylation ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). To determine the number of phosphorylated residues in each fragment, we phosphorylated the fragments 1--3 *in vitro* with extracts from oocytes collected at MI (GVBD), interkinesis (+1 hr) or MII arrest. The phosphorylated fragments were purified, digested and analysed by 2D phosphopeptide mapping ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Fragment 1 yielded four main phosphopeptides (pp 1--4), with a weaker one detectable only after a long exposure ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}, pp 5). Fragment 2 contained a single phosphopeptide (pp 6), while fragment 3 had six additional phosphopeptides (pp 7--12). These phosphopeptide patterns were qualitatively maintained from MI to MII ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). We then compared these 2D phosphopeptide maps with those obtained using recombinant ERK2 or Cdk1/cyclin B ([Figure 2C](#fig2){ref-type="fig"}). ERK2 generated pp 1--6 and pp 10, whereas Cdk1/cyclin B produced pp 1--3 (albeit with low efficiency), 8, 9 and 11--12. In addition, both purified kinases generated other phosphopeptides not observed after phosphorylation with oocyte extract (marked with an asterisk). The migration of some of the phosphopeptides was consistent with phosphorylation at multiple residues in the same peptide. To determine the identity of these residues, we analysed by mass spectrometry either FL xCPEB4 or N-terminal fragments that had been phosphorylated *in vitro* with MII oocyte extracts or recombinant ERK2 or Cdk1/cyclin B. A total of twelve phosphorylation sites in the NTD of xCPEB4 were identified, all of which were evolutionarily conserved ([Figure 2D](#fig2){ref-type="fig"}). Importantly, xCPEB4 phosphosites S97, S250, S253, T324, S328 and S330 were previously identified as phosphorylated residues in CPEB4 mammalian orthologs by high-throughput mass spectrometry screenings (PhosphoSitePlus; <http://www.phosphosite.org>).10.7554/eLife.19298.004Figure 2.ERK2 and Cdk1 phosphorylate the xCPEB4 NTD.(**A**, **B**) *In vitro* kinase assay of (**A**) recombinant FL xCPEB4 or (**B**) fragments (1, 2 and 3) with metaphase II oocyte extracts treated with specific kinase inhibitors (roscovitine, Cdk inhibitor; SL0101, p90Rsk inhibitor; BI-2536, Plk1 inhibitor; U0126, MEK inhibitor; and FR180204, ERK inhibitor). DMSO was used as a negative control. The percentage of phosphorylation compared to DMSO is indicated (autoradiography, ^32^P). A representative experiment from three independent biological replicates is shown. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}--[2](#fig2s2){ref-type="fig"}. (**C**) Two-dimensional phosphopeptide maps of xCPEB4 fragments (1, 2 and 3) phosphorylated with metaphase II (MII) oocyte extracts or with recombinant ERK2 or Cdk1/cyclin B. Phosphopeptides were resolved by thin-layer electrophoresis (TLE) followed by thin-layer chromatography (TLC). Arrows indicate sample origin. Phosphopeptides detected in MII were numbered. Asterisks (\*) indicate phosphopeptides generated with recombinant kinases not present in MII. A representative experiment from three independent biological replicates is shown. See also [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}. (**D**) Disorder tendency (PONDR VL-TX predictor) and mass spectrometry phosphorylation site identification of xCPEB4. Asterisks (\*) indicate phosphosites identified with MII extracts. Bold letters indicate phosphosites identified with either ERK2 or Cdk1/cyclin B. Green indicates ERK2 phosphorylation sites, while purple indicates Cdk1 phosphorylation sites. Red lines represent large disordered regions. The xCPEB4 fragments used are outlined. See also [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.004](10.7554/eLife.19298.004)10.7554/eLife.19298.005Figure 2---figure supplement 1.Loading controls for *in vitro* kinase assays with inhibitors.(**A**) Loading control for [Figure 2A](#fig2){ref-type="fig"}, in a Coomassie blue--stained gel. (**B**) Loading control for [Figure 2B](#fig2){ref-type="fig"}, in a Coomassie blue--stained gel.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.005](10.7554/eLife.19298.005)10.7554/eLife.19298.006Figure 2---figure supplement 2.*In vitro* kinase assay with Cdk1 and ERK2 immunodepleted extracts.(**A**) *In vitro* kinase assay of recombinant xCPEB4 full-length protein (FL), using metaphase II oocyte extracts immunodepleted for Cdk1 or Cdk1/ERK2. IgG was used as negative control. The upper panel shows the autoradiography (^32^P), while the lower panel shows the loading control in a Coomassie blue-stained gel. (**B**) Western blot showing the efficiency of depletion of Cdk1 and ERK2. Tubulin was used as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.006](10.7554/eLife.19298.006)10.7554/eLife.19298.007Figure 2---figure supplement 3.Two-dimensional phosphopeptide maps kinetic.Two-dimensional phosphopeptide maps of xCPEB4 fragments (1, 2 and 3) phosphorylated with oocytes extracts collected at indicated times (GVBD, germinal vesicle breakdown; MII, metaphase II). Phosphopeptides were resolved by thin-layer electrophoresis (TLE) followed by thin-layer chromatography (TLC). Arrows indicate sample origin. Phosphopeptides are numbered. Three independent biological replicates were performed, with equivalent findings each time.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.007](10.7554/eLife.19298.007)10.7554/eLife.19298.008Figure 2---figure supplement 4.Confirmation of detected phosphosites.(**A**, **B**) Two-dimensional phosphopeptide maps of xCPEB4 fragments (1, 2 and 3), wild-type (WT) or phosphorylation mutants, phosphorylated with (**A**) metaphase II oocyte extract or (**B**) recombinant ERK2 or Cdk1/cyclin B. Phosphopeptides were solved by TLE followed by TLC. Arrows indicate sample origin. Phosphopeptides detected in WT conditions are numbered. Asterisks indicate unspecific phosphopeptides present only in xCPEB4 mutants. The mutations are specified at the bottom of panel **A**. (**C**) Lambda-phosphatase assay (λ) using extracts from oocytes overexpressing HA-CPEB4 collected at the indicated times (VI, prophase I; MII, metaphase II). Wild-type (WT) HA-CPEB4 and the 12A mutant (with 12 phosphorylation sites mutated to alanine) were analysed. The phosphorylation status of xCPEB4 was determined by western blot with anti-HA antibody and anti-tubulin (as a loading control). The control, C, corresponds to non-injected oocytes. Three independent biological replicates were performed, with equivalent findings each time.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.008](10.7554/eLife.19298.008)

To confirm that the phosphopeptides detected by 2D phosphopeptide mapping corresponded to the identified phosphosites, we generated a mutant version of the three N-terminal fragments by converting the serine/threonine residue to aspartic acid at the indicated sites, producing fragment 1 (S18/38/40/97D), fragment 2 (S250/253D) and fragment 3 (T324/S328/330/351/357/362D). These mutated fragments were phosphorylated with MII extracts or recombinant ERK2 or Cdk1/cyclin B ([Figure 2---figure supplement 4A,B](#fig2s4){ref-type="fig"}). Based on the resulting 2D phosphopeptide maps, we determined that most of the xCPEB4 phosphorylation sites had been identified. However, the mutated xCPEB4 fragments still contained three phosphorylation sites, corresponding to pp 1, 2 and 7, that were not detected in the mass spectrometry analysis. Accordingly, mutation of the 12 identified residues to alanine (12A) did not abolished the slower migration of xCPEB4 expressed in MII oocytes ([Figure 2---figure supplement 4C](#fig2s4){ref-type="fig"}). Thus, we conclude that xCPEB4 is phosphorylated in at least 12 sites, which most likely correspond to ERK2-mediated (S18/38/40/97/250/253/351) and Cdk1-mediated (T324/S328/330/357/362) target residues. Most of the residues we identified are in regions of the NTD predicted to have relatively low disorder ([Figure 2D](#fig2){ref-type="fig"}), as determined by PONDR VL-TX (Predictors of Naturally Disordered Regions; <http://www.pondr.com>).

xCPEB4 phosphorylation is required for cytoplasmic polyadenylation and meiotic progression {#s2-2}
------------------------------------------------------------------------------------------

We next tested whether these phosphorylation events are required for xCPEB4 activity in promoting cytoplasmic polyadenylation during the second meiotic progression.

First, we analysed the capacity of phospho-mimetic or phospho-null variants to compete or substitute endogenous xCPEB4. For this purpose, we followed the polyadenylation of a radioactive *Emi2* 3′-UTR probe microinjected into oocytes. Due to its arrangement of CPEs and the presence of AU-rich elements (AREs), *Emi2* mRNA is polyadenylated in the third (late-late) wave of cytoplasmic polyadenylation that takes place in interkinesis and MII ([@bib4]; [@bib39]) and which is supported by xCPEB4 ([@bib20]). In this assay, overexpression of active or activatable xCPEB4 functionally replaces the endogenous xCPEB4 and therefore sustains *Emi2* mRNA polyadenylation, whereas a non-activatable CPEB4 variant reaches a competitive equilibrium with the endogenous protein, shortening the poly(A) tail of the target mRNA ([@bib1]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Mutation of all 12 xCPEB4 phosphorylated residues to alanine (12A) not only inactivated the protein, abolishing its capacity to support cytoplasmic polyadenylation ([Figure 3A,B](#fig3){ref-type="fig"}) but was also a better competitor of polyadenylation than a truncated variant of xCPEB4 lacking the NTD ([Figure 3C](#fig3){ref-type="fig"}), suggesting that the 12A mutant promotes poly(A) tail shortening. The mutant 12Am, an xCPEB4 phospho-null mutant that additionally cannot bind RNA (with mutations at Y490A and K595A), did not influence competition for polyadenylation ([@bib1]) ([Figure 3A,B](#fig3){ref-type="fig"}), indicating that the competition effect requires RNA binding. In contrast, a phospho-mimetic xCPEB4 variant (12D), in which all the phosphosites were mutated to aspartic acid, was even less competitive than the WT xCPEB4 ([Figure 3A,B](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), suggesting that this mutant is constitutively active. xCPEB4 mutants in which only the seven ERK2 phosphorylation sites (7A) or the five Cdk1 phosphorylation sites (5A) were mutated to alanine showed partial and additive effects, indicating that these two kinases contribute equally to the activation of xCPEB4 ([Figure 3D,E](#fig3){ref-type="fig"}). Other partial mutations (10A and 8A; [Figure 3D,E](#fig3){ref-type="fig"}; [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) also showed a partial and additive effect for the combined accumulation of mutations, indicating that all 12 phosphorylation events, mediated by the two kinases, are equally important to fully activate xCPEB4, and that a minimum of 10 phosphosites are required. Compared to 12Am, the wild-type CPEB4 (WT) was slightly competitive with endogenous CPEB4 protein, most likely due to inefficient activation or recruitment of co-factors. For this experiment, xCPEB4 variants were expressed from an mRNA where CPEB4-3'UTR was substituted by a non-CPE regulated 3'-UTR, allowing the mutant expression to scape the cell cycle regulation of endogenous CPEB4.10.7554/eLife.19298.009Figure 3.xCPEB4 hyperphosphorylation is required for cytoplasmic polyadenylation and meiotic progression.(**A**--**E**) *In vivo* competition assays. (**A**, **D**) *Emi2* 3′-UTR radioactive probe polyadenylation in the absence (--) or presence (+) of progesterone (P) in oocytes overexpressing wild-type (WT) HA-xCPEB4 or the following mutants: 12A or 12D, which have the 12 phosphosites mutated to alanine or aspartic acid, respectively; 12Am, 12A mutant with two additional mutations that disrupt RNA binding in the RBD; 10A, with all the identified phosphosites except S18 and S40 mutated to alanine; 8A, with S250/253/T324/S328/330/351/357/362 mutated to alanine; 7A, with ERK2 phosphosites mutated to alanine; 5A, with Cdk1 phosphorylation sites mutated to alanine. The dashed line marks the median polyadenylation in the WT. (**B**, **C**, **E**) Percentage of competition of polyadenylation calculated from three independent biological replicates. Results are shown as means and SEM. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}--[2](#fig3s2){ref-type="fig"}. (**F**, **G**) Rescue experiment. Oocytes were injected with xCPEB4 sense or antisense (as) oligonucleotides (NI, non-injected oocytes). After 16 hr, oocytes were injected with mRNAs encoding WT HA-xCPEB4 or the 12A or 12D phosphorylation mutants. (**F**) Oocytes were collected at metaphase II, fixed and stained with Hoechst. A representative image of each phenotype observed, with aligned or misaligned chromosomes, is shown (PB, first polar body; MII, second metaphase plate; chr, misaligned chromosomes). The percentage of oocytes with each phenotype is plotted in the graph (*n* = 10). The red line marks the percentage of oocytes with aligned chromosomes in the antisense condition. Scale bar, 10 µm. A representative experiment from three independent biological replicates is shown. (**G**) RNA from metaphase II oocytes was extracted and the polyadenylation status of endogenous *Emi2* mRNA was measured by Poly(A) tail (PAT) assay followed by Southern blot. See also [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}, [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.009](10.7554/eLife.19298.009)10.7554/eLife.19298.010Figure 3---figure supplement 1.Experimental design and analysis of the competition experiment.(**A**) Schematic diagram of the competition experiment. Wild-type xCPEB4 (blue) or phospho-null (\'A mut\'; in orange) or phospho-mimetic (\'D mut\'; in green) mutants were overexpressed in *X. laevis* oocytes. After an overnight incubation, the oocytes were injected with a radiolabelled *Emi2* 3′-UTR RNA probe in order to follow polyadenylation upon progesterone stimulation. The *Emi2* 3′-UTR radioactive probe is shown in black, with a grey box highlighting the CPE sequence (the three CPE elements present in the probe are shown as one for simplicity). The polyadenylation status of the RNA probe under the specific conditions is shown. Endogenous xCPEBs and the polyadenylation machinery are depicted in grey. (**B**) Quantification method to determine the percentage of competition by wild-type HA-CPEB4 and phosphorylation mutants. Using the Fiji software, the intensity profiles of the blue rectangles were plotted. The percentage of competition was calculated with the formula shown, using the measurement of the distance from the top of the lane to the peak of maximum intensity (x).**DOI:** [http://dx.doi.org/10.7554/eLife.19298.010](10.7554/eLife.19298.010)10.7554/eLife.19298.011Figure 3---figure supplement 2.Expression levels of xCPEB4 variants used in competition experiments.(**A--C**) Western blots with anti-HA antibody to show the levels of overexpression in the competition assays. (**A**) Relative to [Figure 3A,B](#fig3){ref-type="fig"}. (**B**) Relative to [Figure 3C](#fig3){ref-type="fig"}. (**C**) Relative to [Figure 3D,E](#fig3){ref-type="fig"}. Tubulin was used as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.011](10.7554/eLife.19298.011)10.7554/eLife.19298.012Figure 3---figure supplement 3.*In vivo* rescue experiment.(**A**) *In vivo* rescue experiment. Oocytes were injected with sense or antisense (as) xCPEB4 oligonucleotides (NI, non-injected oocytes). After 16 hr, oocytes were injected with mRNAs encoding wild-type (WT) HA-xCPEB4 or the phosphorylation mutant 12A, 12D, 7A, or 5A. Oocytes were collected at metaphase II, fixed and stained with Hoechst. The percentage of oocytes with each phenotype (e.g. aligned or misaligned chromosomes) is plotted in the graph (*n* = 15). The red line marks the percentage of oocytes with aligned chromosomes in the antisense condition. (**B**) Western blot with anti-HA antibody to show the level of overexpression in the rescue experiment from [Figure 3F](#fig3){ref-type="fig"}. (**C**) Western blot with anti-HA antibody to show the level of overexpression in the rescue experiment from [Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}. Tubulin was used as a loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.012](10.7554/eLife.19298.012)10.7554/eLife.19298.013Figure 3---figure supplement 4.xCPEB4 does not differentially interact with cofactors depending on its phosphorylation status.(**A**) Immunoprecipitation of HA-xCPEB4 12A (with the 12 phosphosites mutated to alanine) or HA-xCPEB4 12D (with the 12 phosphosites mutated to aspartic acid) in metaphase II with an anti-HA antibody. Non-injected oocytes were used as a control, C. In the upper panel, half of the immunoprecipitation was resolved in a 4--20% gradient SDS-PAGE and stained with silver staining. In the lower panel, the other half of the samples was loaded in SDS-PAGE but not resolved. The gel was excised and analysed by mass spectrometry. See also [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. (**B**) Immunoprecipitation of HA-xCPEB4, either WT or a phosphosite mutant of 12A or 12D (with the 12 phosphorylation sites mutated to alanine or aspartic acid, respectively) with an anti-HA antibody. Metaphase II oocytes were used. The co-immunoprecipitation of GLD2 was assessed by western blot. Non-injected oocytes were used as a control, C. Input corresponds to WT in MII. A representative experiment from three independent biological replicates is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.013](10.7554/eLife.19298.013)

Second, we explored the capacity of various xCPEB4 phosphorylation mutants to compensate for the depletion of endogenous xCPEB4 in the progression of meiosis to MII arrest, as well as in the polyadenylation of an endogenous MII target mRNA (*Emi2*). Oocytes depleted of xCPEB4 completed the first meiotic division normally but failed to properly assemble chromosomes into a single metaphase plate in MII, displaying scattered chromosomes as compared to control oocytes ([Figure 3F](#fig3){ref-type="fig"}). Nevertheless, xCPEB4-depleted oocytes were able to properly extrude the polar body, indicating that the first meiotic division was completed successfully. Furthermore, xCPEB4 depleted oocytes failed to properly polyadenylate *Emi2* mRNA in the second meiotic division ([Figure 3G](#fig3){ref-type="fig"}). We next overexpressed xCPEB4, using WT and phosphorylation mutants under the control of xCPEB4 3′-UTR, in xCPEB4-depleted oocytes. The WT and 12D xCPEB4 forms, but not the 12A mutant, rescued chromosomal assembly in the MII metaphase plate, as well as *Emi2* polyadenylation ([Figure 3F,G](#fig3){ref-type="fig"}; [Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). Consistent with the observation that the 5A and 7A mutants were partially competitive for polyadenylation (see [Figure 3E](#fig3){ref-type="fig"}), only the fully phosphorylated xCPEB4 was able to rescue the MII meiotic arrest ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Thus, we conclude that ERK2 and Cdk1 phosphorylate and activate xCPEB4 in the 12 identified sites in order to sustain cytoplasmic polyadenylation in the second meiotic division.

xCPEB4 phosphorylation regulates its capacity to phase separate into liquid-like droplets {#s2-3}
-----------------------------------------------------------------------------------------

To define the functional consequence of xCPEB4 phosphorylation, we first analysed whether these phosphorylation events affect its capacity to recruit cofactors, as is the case for CPEB1, the phosphorylation of which by AurKA causes a switch of activity from recruiting the deadenylase PARN to assembling the CPSF/GLD2 polyadenylation complex ([@bib3]; [@bib23]; [@bib30]). We overexpressed HA-tagged 12A (phospho-null) and 12D (phospho-mimetic) xCPEB4 mutants in oocytes and, after progesterone stimulation, analysed the co-immunoprecipitated proteins by SDS silver staining and mass spectrometry. Most of the identified interacting proteins were enriched for both mutants, with some exceptions, such as chaperones (Hspd1) and RNA helicases (Ddx1 and Ddx20), which were present only in the 12A immunoprecipitation ([Figure 3---figure supplement 4A](#fig3s4){ref-type="fig"}; [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). We specifically tested whether the two mutants could still recruit GLD2, the cytoplasmic poly(A) polymerase directly responsible for poly(A) tail elongation. Again, we did not detect any differences between the phospho-mimetic and the phospho-null xCPEB4 mutants ([Figure 3---figure supplement 4B](#fig3s4){ref-type="fig"}).

We next addressed whether phosphorylation of xCPEB4 causes changes in its subcellular localization that could explain the differences in its activity. We overexpressed FL or NTD GFP-tagged xCPEB4 constructs, using either the wild-type or the 12A and 12D mutants for each, in U2OS cells. GFP and the GFP-xCPEB4 RNA-binding domain (RBD) were used as controls ([Figure 4A,B](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Both WT and 12A GFP-xCPEB4 phase-separated into cytoplasmic spherical granules when expressed in U2OS cells. In contrast, the 12D mutant exhibited diffuse cytoplasmic distribution ([Figure 4A,C](#fig4){ref-type="fig"}). The WT, 12A and 12D xCPEB4 NTDs expressed in U2OS cells distributed in patterns similar to their corresponding FL variants ([Figure 4B,D](#fig4){ref-type="fig"}). The controls, of either GFP alone or the GFP-xCPEB4 RBD, exhibited diffuse nuclear and cytoplasmic distribution, suggesting that the RBD does not contribute to the granular distribution of xCPEB4. The analysed cells showed equivalent fluorescence intensities ([Figure 4E,F](#fig4){ref-type="fig"}), implying that the differential ability to phase separate is not a consequence of distinct protein concentration. These results indicate that, when non-phosphorylated, the intrinsically disordered NTD of xCPEB4 phase separates into large assemblies in non-mitotic cells. Co-staining of P-bodies and stress granule markers (4E-T and DDX6; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}) showed no clear co-localization of these with xCPEB4. Thus, although CPEB4 re-localizes to stress granules in response to arsenite ([@bib10]), inactive xCPEB4 in non-stressed cells forms cytoplasmic granules that differ from P-bodies or stress granules. To better characterize the nature of these assemblies, we performed FRAP experiments with FL or NTD GFP-xCPEB4. We determined a half-time of maximum recovery (Half Max) of 1.8 ± 0.11 s for FL GFP-xCPEB4 and of 0.76 ± 0.07 s for the NTD ([Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These fast recovery rates indicate that the molecules forming the granules had a liquid-like behaviour and were in constant exchange with the surrounding cytoplasm. This feature, together with the spherical shape of the granules and the fact that we could observe fusion events over time ([Figure 5B](#fig5){ref-type="fig"}; [Video 1](#media1){ref-type="other"}), suggests that xCPEB4 is able to phase separate into liquid-like droplets. The difference in recovery between the FL and the NTD forms indicates that the RBD of xCPEB4, and most probably the bound mRNA, are not required for the self-assembly but influence the dynamics of these droplets.10.7554/eLife.19298.014Figure 4.Non-phosphorylated NTD promotes xCPEB4 distribution in cytoplasmic granules.(**A, B**) Representative image of (**A**) full-length eGFP-xCPEB4 or (**B**) the N-terminal domain, using the wild-type (WT) or phosphorylation mutants 12A or 12D (with the 12 phosphorylation sites mutated to alanine or aspartic acid, respectively), transfected in U2OS cells. As controls, eGFP and eGFP-RBD (RNA-binding domain) were used. Merge images show eGFP in green and DAPI in blue. Scale bar, 25 µm. (**C**, **D**) Quantification of the different expression patterns observed in [Figure 4A](#fig4){ref-type="fig"} (**C**) and [Figure 4B](#fig4){ref-type="fig"} (**D**). 100 cells were analysed and classified as having a granular (grey bars) or diffuse (white bars) expression pattern. The percentage of cells with each phenotype was calculated from three independent biological replicates. Results are shown as means and SEM. Significance was addressed with a Sidak's multiple comparisons test. \*p\<0.05; ns, non-significant. (**E**, **F**) Average cell intensity (*n* = 100 cells) of the cells analysed in [Figure 4C](#fig4){ref-type="fig"} (**E**) and [Figure 4D](#fig4){ref-type="fig"} (**F**). Results are shown as means (SD). Significance was determined by the Student's t-test. \*p\<0.05; ns, non-significant. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}--[2](#fig4s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.014](10.7554/eLife.19298.014)10.7554/eLife.19298.015Figure 4---figure supplement 1.Expression of eGFP-xCPEB4 variants.Western blot with anti-GFP antibody of U2OS cells transfected with eGFP-xCPEB4 (full-length, the N-terminal domain (NTD) or the RNA-binding domain (RBD)). The wild-type (WT) and the phosphorylation mutants 12A or 12D were analysed. Tubulin was used as a loading control. Asterisks (\*) indicate unspecific bands.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.015](10.7554/eLife.19298.015)10.7554/eLife.19298.016Figure 4---figure supplement 2.xCPEB4 cytoplasmic granules are distinct from P-bodies or stress granules.Immunofluorescence of 4E-T and DDX6 in U2OS cells overexpressing full-length eGFP-xCPEB4. eGFP is shown in green; 4E-T and DDX6, in red; and DAPI, in blue. Scale bar, 20 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.016](10.7554/eLife.19298.016)10.7554/eLife.19298.017Figure 5.xCPEB4 cellular assemblies show liquid-like behaviours.(**A**) Fluorescence recovery after photobleaching (FRAP) of eGFP-xCPEB4 full-length (green) or the N-terminal domain (NTD, grey) transfected in U2OS cells. Raw data (dots) and average recovery curves (line) are shown. Error bars show 95% confidence interval. The half-time of maximum recovery (Half Max) and the mobile fraction are specified as means and SEM (*n* = 20). See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. (**B**) Sequential images showing fusion events of xCPEB4 granules (left). The relative intensities of the fusing granules (1 and 2) and the resulting granule (3) are shown, as well as the expected intensity from the fusion of granules 1 and 2 (1 + 2) (right). See also [Video 1.](#media1){ref-type="other"}**DOI:** [http://dx.doi.org/10.7554/eLife.19298.017](10.7554/eLife.19298.017)10.7554/eLife.19298.018Figure 5---figure supplement 1.Fitting FRAP curves.Fitting FRAP curves (a single exponential model was used to fit the data). Single fitting curves are shown in dotted lines. The average fitting curve is shown in black. The average recovery curve is also shown (eGFP-xCPEB4 FL, green; eGFP-xCPEB4 NTD, grey).**DOI:** [http://dx.doi.org/10.7554/eLife.19298.018](10.7554/eLife.19298.018)Video 1.Live imaging of U2OS cells transfected with GFP-xCPEB4 NTD.The fusion of two liquid-like droplets is shown inside the green box.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.019](10.7554/eLife.19298.019)10.7554/eLife.19298.019

We next sought to determine whether the phospho-dependent transition between the liquid-like droplet state and the monomeric active state of CPEB4 occurs endogenously. During meiosis, xCPEB4 accumulates in MII, during which ERK2 and Cdk1 are already active; consequently, xCPEB4 only exists in a phosphorylated active state. Thus, to evaluate the transition between the liquid-like droplet state and the monomeric active state of endogenous CPEB4, we studied human CPEB4 (hCPEB4) during the mitotic cell cycle in U2OS cells (hCPEB4 and xCPEB4 share 93% of identity and the identified phosphorylation sites are conserved). To this end, cells were synchronized in mitosis (with nocodazole or RO-3306) and selected by mitotic shake-off. As in meiosis, endogenous hCPEB4 presented a mobility shift in M-phase that disappeared upon lambda-phosphatase treatment, indicating that hCPEB4, like xCPEB4, is phosphorylated in M-phase ([Figure 6A](#fig6){ref-type="fig"}). To assess if this phosphorylation reflected the transit from the liquid-like droplet state to the monomeric state, we first detected endogenous hCPEB4, in mitotic and non-mitotic cells, by immunofluorescence. Even though it did appear that in mitotic cells the distribution of hCPEB4 was more diffuse than in G1 cells, the change in size/shape of mitotic cells, as well as the increase of hCPEB4 levels during mitosis, made it difficult to quantify the distribution of hCPEB4 along the cell cycle phases ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To avoid these limitations, we analysed the formation of hCPEB4 assemblies by sedimentation in sucrose gradients. Vinculin was used as a reference control. 75% of unphosphorylated hCPEB4 from asynchronous cells was located in dense sucrose fractions (15--23), indicating that CPEB4 is forming large assemblies. In contrast, 84% of phosphorylated hCPEB4 from mitotic cells was located in lighter sucrose fractions (1--13), suggesting that it is in a monomeric state ([Figure 6B,C](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). We next analysed the association of known CPEB1-co-factors (PARN, Symplekin, CPSF2 and GLD2) with phosphorylated/monomeric or unphosphorylated/phase-separated CPEB4. First, we tested the distribution of those cofactors along the sucrose gradients ([Figure 6B](#fig6){ref-type="fig"}). Symplekin, CPSF2 and GLD2 were found in both dense and light fractions, co-migrating with CPEB4 in both the liquid-like droplet state and the monomeric state. CPEB4 Co-IPs confirmed that Symplekin and CPSF2 interact with phosphorylated and unphosphorylated CPEB4 ([Figure 7A](#fig7){ref-type="fig"}), as did GLD2 with xCPEB4 12A and 12D mutants in the oocytes ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). These results are consistent with the association of Symplekin, CPSF and GLD2 to both repressor and activator CPEB1-complexes ([@bib3]; [@bib23]). However, PARN distribution was restricted to light fractions ([Figure 6B](#fig6){ref-type="fig"}), indicating that PARN is not responsible of mRNA deadenylation in CPEB4 liquid-like droplets. We also analysed ribosome association (S6), which despite of being in the dense fractions of the gradients were not part of CPEB4 liquid-like droplets ([Figuers 6B](#fig6){ref-type="fig"} and [7A](#fig7){ref-type="fig"}). Thus, suggesting that CPEB4 liquid-like droplets are not active in translation. Altogether, these results are consistent with the mass spectrometry results ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}), indicating that the change in CPEB4 activity upon phosphorylation are linked to its phase-transition and not to the differential recruitment of cofactors.10.7554/eLife.19298.020Figure 6.Endogenous hCPEB4 is phosphorylated and monomeric in M-phase.(**A**) Lambda-phosphatase assay (λ) of cell extracts from asynchronous (Async.) or M-phase U2OS cells synchronized with either nocodazole (Noco.) or RO-3306. Western blots against hCPEB4, the mitotic marker phospho-histone H3 and Vinculin (as a loading control) are shown. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. (**B**) Cell extracts from asynchronous or M-phase U2OS cells (synchronized with nocodazole) were resolved in 5--40% sucrose gradients. Distribution of hCPEB4, Symplekin, CPSF2, PARN, GLD2 and the ribosomal protein S6 along the gradient are shown. Vinculin was used as a reference control. Asterisks indicate unspecific bands. See also [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. (**C**) Quantification of hCPEB4, from asynchronous and M-phase cells, distribution along 5--40% sucrose gradients. Results, from three independent biological replicates, are shown as means and SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.020](10.7554/eLife.19298.020)10.7554/eLife.19298.021Figure 6---figure supplement 1.Immunofluorescence of endogenous hCPEB4 in U2OS cells.Immunofluorescence of hCPEB4 in U2OS cells. Interphase (1) and M-phase (2) cells are indicated. Merge images show hCPEB4 in green and DAPI in blue. Scale bar, 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.021](10.7554/eLife.19298.021)10.7554/eLife.19298.022Figure 6---figure supplement 2.hCPEB4 (from M-phase cells synchronized with RO-3306) distribution along 5--40% sucrose gradients.Cell extracts from M-phase U2OS cells (synchronized with RO-3306) were resolved in 5--40% sucrose gradients. Distribution of hCPEB4, Symplekin, CPSF2, PARN, GLD2 and the ribosomal protein S6 along the gradient are shown. Vinculin was used as a reference control. Asterisks indicate unspecific bands.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.022](10.7554/eLife.19298.022)10.7554/eLife.19298.023Figure 7.Phosphorylated/monomeric and non-phosphorylated/phase-separated hCPEB4 equally interact with cofactors and bind target mRNAs.(**A**) Immunoprecipitation of hCPEB4 from asynchronous ('Asy') and M-phase ('M', synchronized with nocodazole) U2OS cells. IgG was used as negative control. The Co-IPs of Symplekin, CPSF2 and the ribosomal protein S6 were analysed. Asterisks indicate unspecific bands. (**B**) RNA-immunoprecipitation (RIP) of hCPEB4 from 5--40% sucrose gradients dense (17--21) and light (5--9) fractions. The upper panel shows hCPEB4 from asynchronous cells, while the lower panel shows hCPEB4 from M-phase cells (synchronized with nocodazole). The binding of hCPEB4 to *Cdc20*, *Spop* and *Mnt* target mRNAs was assessed by RT-qPCR. Results are shown as % of mRNA bound by hCPEB4 in each fraction (results were normalized by the negative control *Gapdh*). Two independent biological replicates, each one with three technical replicates, are shown as means and SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.023](10.7554/eLife.19298.023)

We then checked CPEB4 mRNA association in its two different states, phosphorylated/monomeric and unphosphorylated/phase-separated, analysing three known targets that are specifically polyadenylated and activated in mitosis and in a CPEB4 dependent manner: *Cdc20*, *Spop* and *Mnt* ([@bib34]). Thus, we performed RNA-co-immunoprecipitation of CPEB4 from light (5--9) and dense (17--21) sucrose gradient fractions in asynchronous and M-phase cells ([Figure 7B](#fig7){ref-type="fig"}). In asynchronous cells, 63% of *Cdc20*, 92% of *Spop* and 78% of *Mnt* mRNAs are bound by the CPEB4 in large-assemblies. In M-phase synchronized cells, 75% of *Cdc20*, 83% of *Spop* and 88% of *Mnt* mRNAs are bound by the free CPEB4 ([Figure 7B](#fig7){ref-type="fig"}). These results show that both states of CPEB4 are equally able to bind target mRNAs and that in asynchronous cells, the larger proportion of these CPEB4 targets are in the liquid-like droplets devoiced of ribosomes and, therefore, translationally inactive.

We concluded that, in interphase, unphosphorylated CPEB4 phase separates into liquid-like droplets that recruit mRNAs but are inactive for cytoplasmic polyadenylation and translation ([@bib18]), whereas in M-phase, CPEB4 is phosphorylated by ERK2 and Cdk1 and recovers its monomeric form, which can drive the cytoplasmic polyadenylation of target mRNAs.

To further define whether CPEB4 assemblies correspond to self-association of CPEB4, we purified the NTD of WT, 12A, and 12D xCPEB4 variants and determined their intrinsic capacity to phase separate into liquid-like droplets *in vitro* by means of dynamic light scattering (DLS) and transmission electron microscopy (TEM). DLS measurements revealed that the WT and 12A NTDs had a hydrodynamic diameter \> 1000 nm, while 12D presented a diameter of 10 nm ([Figure 8A](#fig8){ref-type="fig"}), which is in good agreement with that predicted for an intrinsically disordered protein of 459 residues. The hydrodynamic diameter \> 1000 nm observed for the WT NTD, but not the equivalent 12A mutant, reverted to 10 nm when the protein was phosphorylated *in vitro* with ERK2 and Cdk1/cyclin B ([Figure 8B,C](#fig8){ref-type="fig"}). Thus, phosphorylation of the 12 identified residues by these two kinases controls the formation of large and dynamic self-assemblies through interactions of xCPEB4's N-terminal intrinsically disordered regions. When analysed by TEM, the unphosphorylated WT and the 12A xCPEB4 NTDs, but not the phosphorylated WT or the 12D NTDs, formed spherical structures that resemble liquid-like droplets (no fibers were detected in any case) ([Figure 8D](#fig8){ref-type="fig"}).10.7554/eLife.19298.024Figure 8.Purified xCPEB4 forms liquid-like droplets that are regulated by hyperphosphorylation and that specifically recruit CPE-containing mRNAs.(**A**) Dynamic light scattering of the xCPEB4 N-terminal domain (NTD), either as wild-type (WT) or the 12A or 12D phosphorylation mutant (with the 12 phosphorylation sites mutated to alanine or aspartic acid, respectively). (**B**, **C**) Dynamic light scattering of the xCPEB4 NTD, either as WT (**B**) or the phospho-null 12A mutant (**C**), upon phosphorylation (+Kin) with ERK2 and Cdk1/cyclin B. The size distribution by volume is plotted. A representative experiment from three independent replicates is shown. (**D**) Transmission electron microscopy of the xCPEB4 NTD, either as WT or the 12A or 12D phosphorylation mutant. WT phosphorylated with ERK2 and Cdk1/cyclin B is shown at the right (WT +Kin). Scale bar, 1 µm. (**E**) Coomassie-stained gel of the input (4%) and the flow-through (FT, 20%) after passing through 0.22-µm-pore-size cellulose acetate filters. NTD, xCPEB4 N-terminal domain; FL, full-length xCPEB4; FL +Kin, FL phosphorylated with ERK2 and Cdk1/cyclin B. Asterisks show degradation products. (**F**) Cyclin B1--3′-UTR or B1-123--3′-UTR radioactive probe retention on 0.22 µm cellulose acetate filters after incubation with the indicated proteins: NTD, xCPEB4 N-terminal domain; FL, full-length xCPEB4; FL +Kin, FL phosphorylated with ERK2 and Cdk1/cyclin B. (**G**) Quantification of the cyclin B1--3′-UTR and B1-123--3′-UTR radioactive probe retention from three independent experiments. Results are shown as means and SEM. Significance was determined by the Student's t-test; \*p\<0.05, \*\*p\<0.005.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.024](10.7554/eLife.19298.024)

We next tested whether the FL protein within the liquid-like droplets could specifically bind CPE-containing RNA. We incubated recombinant xCPEB4 with radiolabelled cyclin B1--3′-UTR derived RNA-probes with (B1) or without (B1-123) CPEs ([@bib39]). Then, this mixture was filtered through 0.22-μm-pore-size cellulose acetate filters, where 1 μm xCPEB4 liquid-like droplets, but not the soluble monomeric protein, were retained. Soluble xCPEB4, was recovered in the flow-through ([Figure 8E](#fig8){ref-type="fig"}). When tested for radiolabelled RNA binding, the membrane-bound FL-xCPEB4 was able to specifically retain the B1 RNA, but not the B1-123 ([Figure 8F,G](#fig8){ref-type="fig"}). This RNA-binding capacity of the liquid-like droplets required the RBD, as the NTD on its own did not retain the radiolabelled probe. Partial phosphorylation of FL-xCPEB4 resulted in a proportional release of phosphorylated xCPEB4 from the liquid-like droplets ([Figure 8E](#fig8){ref-type="fig"}) and a reduction of CPE-containing RNA probe retention in the filter ([Figure 8F,G](#fig8){ref-type="fig"}). Thus, the unphosphorylated NTD of CPEB4 promoted the self-assembly of liquid-like droplets, while the RBD recruited CPE-containing RNAs to this structures.

Discussion {#s3}
==========

At the onset of the PI--MI meiotic transition, CPEB4 synthesis is activated by CPEB1-mediated cytoplasmic polyadenylation of its maternal mRNA ([@bib20]). However, CPEB4 has to be activated before it can sustain polyadenylation in the second meiotic division ([@bib34]). Our results indicate that CPEB4 activation is driven by ERK2- and Cdk1-mediated hyperphosphorylation of at least 12 residues in the intrinsically disordered NTD. Therefore, the sequential functions of CPEB1 and CPEB4 to drive unidirectional progression through the two meiotic divisions result from two redundant mechanisms that are both translational and post-translational ([Figure 9](#fig9){ref-type="fig"}). Thus, CPEB1 is activated by AurKA upon meiotic resumption from PI arrest ([@bib29]), leading to the translation of the mRNAs encoding Mos, cyclin B1 and CPEB4 ([@bib20]; [@bib39]). This in turn activates the kinases ERK2 and Cdk1, which phosphorylate CPEB4 and allow it to sustain cytoplasmic polyadenylation after MI, when AurKA is inactivated ([@bib36]) and PPI (which dephosphorylates CPEB1 S174) expression increases ([@bib4]; [@bib42]). Concomitantly, Cdk1 triggers the degradation of CPEB1 ([@bib28]), thus reinforcing the substitution of CPEB1 by CPEB4 for the second meiotic division ([@bib20]). Hence, CPEB1 and CPEB4 activities are coordinated, not only because CPEB1 controls the synthesis of CPEB4, but also because the same kinase that triggers the degradation of CPEB1---namely, Cdk1---activates CPEB4.10.7554/eLife.19298.025Figure 9.Model to illustrate the sequential and coordinated functions of CPEB1 and CPEB4 in the meiotic cell cycle.The different meiotic phases, as well as the activity profiles of ERK2 (light grey) and Cdk1/cyclin B (dark grey) along meiosis, are shown at the top. The sequential expression and function of xCPEB1 (yellow) and xCPEB4 (blue) are shown below. Orange ovals represent CPEB repression complexes. Orange arrows and orange phosphorylation events (\*) indicate inhibitory effects. Green ovals represent CPEB activation complexes. Green arrows and green phosphorylation events (\*) indicate activating effects. mRNAs activated in the different waves of cytoplasmic polyadenylation are shown in grey boxes. The phase-separation and inactivation that unphosphorylated CPEB4 experiences in non-mitotic cells is represented in the dashed box.**DOI:** [http://dx.doi.org/10.7554/eLife.19298.025](10.7554/eLife.19298.025)

Unlike CPEB1, for which phosphorylation leads to the differential recruitment of cofactors, for CPEB4 we have not detected any specific cofactor that could explain the functional switch that CPEB4 experiences upon phosphorylation. Instead, CPEB4 phosphorylation controls its phase separation into liquid-like droplets, which are inactive for cytoplasmic polyadenylation and sequester CPE-containing mRNAs. Thence, our data support the idea that it is the phosphorylation-regulated phase-transition itself, and not the differential binding to positive or negative cofactors, what controls CPEB4 function. Interestingly, this correlation between phosphorylation and dissociation of the liquid-like droplets also occurs during the mitotic cell cycle, indicating that this regulation contributes to the CPEB4-dependent and M-phase--specific activation of CPE-regulated mRNAs ([@bib18]; [@bib34]).

CPEB4 assemblies share the key features of non-membrane--bound organelles that behave like dynamic liquid droplets ([@bib45]). These dynamic, high-density liquid-like droplets are usually formed by repetitive, low-complexity intrinsically disordered regions, which self-assemble in micrometre-sized, near-spherical particles separated spontaneously from aqueous solutions ([@bib2]; [@bib33]). Hence, CPEB4 assemblies are structurally and functionally distinct from the more static and inheritable amyloid-like filaments formed by active CPEB3 multimers ([@bib19]; [@bib25]). Additionally, CPEB4 liquid-like droplets are reminiscent of other two-component models for mRNA recruitment to intracellular granules: RBPs bind to mRNA via an RBD and phase separate by the interaction of their low-complexity sequences ([@bib26]; [@bib33]; [@bib45]). The dynamism of these structures renders potential for regulated reversibility. In the case of CPEB4, its hyperphosphorylation results in the dissociation of the liquid-like droplets, most probably through the disruption of electrostatic interactions along its disordered NTD. This mechanism provides a novel example of how phase-transitions driven by disordered regions can be regulated post-translationally ([@bib33]; [@bib19]), and unveils a new mechanism of translational regulation during cell cycle.

Given that CPEB4 has the potential to regulate up to 20% of the genome, with the flexibility of the high-specificity but low-affinity interactions promoted by the NTD and the hysteresis provided by the multisite phosphorylation regulation, it generates a system ideally suited to serve as a hub in scale-free networks ([@bib14]). Indeed, the regulation of CPEB4 by the additive effect of multisite phosphorylations is reminiscent of the ultrasensitive responses that drive irreversible, discrete phase transitions in meiosis, as exemplified by the switch-like regulation of Cdc25C by Cdk1 hyperphosphorylation. Partial phosphorylation of half of the possible sites already provides the highest ultrasensitivity, which may explain the polyadenylation and cell cycle progression effects of the 12A CPEB4 mutant, although it is also phosphorylated in unidentified residues (reviewed in ref. \[[@bib17]\]). Thus, the ultrasensitivity may be driven at least in part by cumulative electrostatic interactions between NTDs ([@bib6]).

Materials and methods {#s4}
=====================

*Xenopus laevis* oocyte preparation {#s4-1}
-----------------------------------

Stage VI oocytes were obtained from *X. laevis* females as described previously ([@bib12]). Maturation was induced with 10 μM progesterone (Sigma-Aldrich, Saint Louis, MO).

Plasmid constructions {#s4-2}
---------------------

For protein purification, xCPEB4 open reading frame (ORF), full length or fragments, was cloned in pET30a vector downstream of the HIS-tag ([@bib20]). For competition and rescue experiments, xCPEB4 ORF and its 3'UTR were cloned in pBSK and an HA-tag was added at the N-terminus (3'UTR nucleotides targeted by the 20AS used for xCPEB4 depletion were not included). The pBSK-Emi2 3'UTR was obtained from ([@bib4]). For cell transfection, xCPEB4 ORF was cloned in pPEU16, which contains an N-terminal OneStrep-eGFP tag, by In-FusionTM (BD Clontech, Mountain View, CA) cloning reaction ([@bib5]).

Mutagenesis {#s4-3}
-----------

Mutagenesis of xCPEB4 phosphorylation sites, as well as Y490 and K595 RNA-binding residues ([@bib1]), was performed with the QuickChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA), following the manufacturer's instructions and using the following mutagenic primers (mutated codons are highlighted in bold):

S18A: 5'-CACTGGGAACAAG**GCA**GCTTTTCCAGTC-3'

S18D: 5'-CACTGGGAACAAG**GAC**GCTTTTCCAGTC-3'

S38/40A: 5'-CATCATCAGAATACA**GCC**CCC**GCC**CCCGCTGCTTTTATA-3'

S38/40D: 5'-CAGAATACA**GAC**CCC**GAC**CCCGCTGCTTTTAT-3'

S97A: 5'-CCTTAGACAAACAGCTC**GCT**CCTAGCCAAAGC-3'

S97D: 5'-CCTTAGACAAACAGCTC**GAT**CCTAGCCAAAGC-3'

S250/253A: 5'-CCAACAGCAAAGGAGA**GCT**CCTGCC**GCT**CCCCATCTGCCTCC-3'

S250/253D: 5'-CCAACAGCAAAGGAGA**GAT**CCTGCC**GAT**CCCCATCTGCCTCC-3'

S324/330A: 5'- CTTAATGGAGGAATA**GCA**CCCTTGAATTCCATA**GCA**CCATTAAAGAAG-3'

S328/330A: 5'-CACCCTTGAAT**GCC**ATA**GCA**CCATTAAAG-3'

S324/328/330D:5'-CTTAATGGAGGAATA**GAT**CCCTTGAAT**GAC**ATA**GAC**CCATTAAAGAAGAAT-3'

S351A: 5'-GGCAGGCCCAAT**GCT**GCCTTTGCAC-3'

S351D: 5'-GGCAGGCCCAAT**GAT**GCCTTTGCAC-3'

S357/362A: 5'-CTTTGCACCAAAA**GCT**TGGATGGATGAC**GCC**TTGAACAGAGC-3'

S357/362D: 5'-CTTTGCACCAAAA**GAT**TGGATGGATGAC**GAC**TTGAACAGAGC-3'

Y490A: 5'-CTTTCCTCCGAAAGGT**GCT**GCGTTCTTGCTGTTCC-3'

K595A: 5'-GAGCTAAAGTACCCC**GCA**GGAGCTGGGCGTG-3'

Antibodies {#s4-4}
----------

Anti-HA (clone 3F10, Sigma-Aldrich), anti-α-Tubulin (clone DM1A, Sigma-Aldrich), anti-Cdk1 (ab18, Abcam, Cambridge, UK), anti-ERK1/ERK2 (9102, Cell Signaling, Danvers, MA), anti-xGLD2 (rabbit polyclonal antibody raised against KRRSDEGNSPYDVKC peptide, *X. laevis*), anti-4E-T (2297, Cell Signaling), anti-DDX6 (PD009, MBL, Nagoya, Japan), anti-hCPEB4 for WB (rabbit polyclonal antibody raised against amino acids 1--302), anti-hCPEB4 for IP (ab83009, Abcam), anti-phospho Histone H3 (Ser 10) (06--570, Merck Millipore, Billerica, MA), anti-Symplekin (610644, BD Transduction Laboratories, Franklin Lakes, NJ), anti-CPSF2 (ab126760, Abcam), anti-PARN (ab89831, Abcam), anti-hGLD2 (AP5092, Abgent, San Diego, CA), anti-S6 (2317, Cell Signaling), anti-Vinculin (ab18058, Abcam).

Lambda protein phosphatase assay (λ-PPase) {#s4-5}
------------------------------------------

Oocytes (injected with 2.43 fmols of *in vitro* transcribed and polyadenylated HA-xCPEB4 RNA) and U2OS cells were lysed with λ-PPase reaction buffer (New England BioLabs, Ipswich, MA) supplemented with 0.4% NP-40 and EDTA-free protease inhibitors (Sigma-Aldrich). λ-PPase (New England BioLabs) reactions were performed following manufacturer's instructions.

Protein purification {#s4-6}
--------------------

HIS-xCPEB4 (full length or fragments) was expressed in *Escherichia coli*. HIS-tagged proteins from the soluble fraction were purified with Ni^2+^-NTA agarose (Qiagen, Hilden, Germany) in buffer J (25 mM Tris-HCl pH 8, 1 M NaCl, 5 mM MgCl~2~, 1% NP-40, 5% Glycerol and 6 M Urea) supplemented with 10 mM imidazole pH 8, EDTA-free protease inhibitor cocktail (Sigma-Aldrich) and 1 mM PMSF. Elution was carried out with elution buffer (25 mM Tris-HCl pH 8, 300 mM NaCl, 5 mM MgCl~2~, 5% glycerol, 6 M urea, 300 mM imidazole and EDTA-free protease inhibitors). Imidazole and urea concentration were reduced by dialysis.

*In vitro* kinase assays {#s4-7}
------------------------

Oocytes were homogenized in H1 kinase buffer (80 mM sodium β-glycerolphosphate pH 7.4, 20 mM EGTA, 15 mM MgCl~2~, 0.5 mM Na~3~VO~4~) supplemented with 0.5% NP-40 and EDTA-free protease inhibitors (Sigma-Aldrich) (10 μl buffer / oocyte) and centrifuged at 12,000 *g* for 10 min at 4°C. 1--4 μg of purified recombinant protein (full-length HIS-xCPEB4 or fragments; H1 protein from Sigma-Aldrich) were incubated at RT for 15 min with 8 μl of oocyte extract, 50 μM ATP and 1 μCi of \[Y-^32^P\] ATP in a final volume of 12 μl. Samples were analysed by SDS-PAGE followed by autoradiography.

For kinase inhibitor assays, 2 μl of metaphase II oocyte extract pre-incubated with specific kinase inhibitors for 30 min at 4°C was used: 33 μM FR180204 (Merck Millipore), 80 μM Roscovitine (Merck Millipore), 0.66 mM SL0101 (Tocris Bioscience, Bristol, UK), 66 nM BI-2536 (BioVision, Milpitas, CA), 130 μM U0126 (Promega, M﻿adison, WI).

For immunodepletion assays, MII oocytes were homogenized in IP lysis buffer (20 mM Tris-HCl pH 8, 0.5% NP-40, 1 mM MgCl~2~ and 100 mM NaCl) supplemented with H1 kinase buffer and EDTA-free protease inhibitors (Sigma-Aldrich) (30 μl / oocyte). 150 μl of oocyte extracts were incubated with 50 μl of Dynabeads protein A (Invitrogen, Carlsbad, CA) bound to 10 μg IgG (Sigma-Aldrich), 10 μg of anti-Cdk1 or 20 μl of anti-ERK1/ERK2, at 4°C during 20 hr. Immunodepleted oocyte extract from 0.25 oocytes were used for the *in vitro* kinase assay.

Kinase reactions with ERK2 and Cdk1/cyclin B were performed following the manufacturer's instructions \[ERK2 (New England Biolabs), Cdk1/cyclin B (Invitrogen)\].

Mass spectrometry analysis of phosphorylated xCPEB4 {#s4-8}
---------------------------------------------------

Mass spectrometry analysis of xCPEB4 phosphorylation sites generated with MII oocyte extracts was carried out at \'CRG/UPF Proteomics Unit, Centre de Regulació Genòmica (CRG), Universitat Pompeu Fabra (UPF), 08003 Barcelona\' as follows: xCPEB4 was phosphorylated *in vitro* with MII oocyte extracts and re-purified with Ni^2+^-NTA agarose (Qiagen). Samples were in-gel digested with 0.3 μg of trypsin (Promega) (fragment 3) or trypsin followed by chymotrypsin (Roche, Basel, Switzerland) (full length, fragments 1 and 2). After digestion, peptides were extracted and cleaned up on a homemade Empore C18 column (3 M, St. Paul, MN). Samples were analysed using a LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to an EasyLC (Thermo Fisher Scientific (Proxeon), Odense, Denmark). Peptides were loaded directly onto the analytical column at 1.5--2 μl/min and were separated by reversed-phase chromatography using a 12 cm column with an inner diameter of 75 μm, packed with 5 μm C18 particles (Nikkyo Technos Co., Ltd. Japan). Chromatographic gradients started at 97% buffer A and 3% buffer B with a flow rate of 300 nl/min, and gradually increased to 93% buffer A and 7% buffer B in 1 min, and to 65% buffer A/35% buffer B in 60 min. Buffer A: 0.1% formic acid in water. Buffer B: 0.1% formic acid in acetonitrile. The mass spectrometer was operated in positive ionization mode with nanospray voltage set at 2.2 kV and source temperature at 250°C. The instrument was operated in DDA mode and full MS scans with 1 micro scans at a resolution of 60,000 were used over a mass range of m/z 250--2000 with detection in the Orbitrap. Auto gain control (AGC) was set to 1E6, dynamic exclusion (60 s) and charge state filtering disqualifying singly charged peptides was activated. In each cycle of DDA analysis, following each survey scan, the top twenty most intense ions with multiple charged ions above a threshold ion count of 5000 were selected for fragmentation at normalized collision energy of 35%. Each sample was injected twice: fragment ion spectra produced via collision-induced dissociation (CID) and via high-energy collision dissociation (HCD). An isolation window of 2.0 m/z, activation time of 0.1 ms and maximum injection time of 100 ms were used. All data were acquired with Xcalibur software v2.2. For data analysis, the Mascot search engine (v2.3, Matrix Science) was used for peptide identification. The data were searched against NCBInr (*Xenopus laevis*). A precursor ion mass tolerance of 10 ppm at the MS1 level was used. Up to three miscleavages for trypsin were allowed. The fragment ion mass tolerance was set to 0.5 Da. Oxidation of methionine, protein acetylation at the N-terminal, and phosphorylation at serine, threonine and tyrosine were defined as variable modifications; whereas carbamidomethylation on cysteines was set as a fix modification. Peptides were filtered using an expectation value \[EXPECT\] cutoff of 0.1.

Mass spectrometry analysis of xCPEB4 phosphorylation sites generated with ERK2 or Cdk1/cyclin B recombinant kinases was done at the Mass Spectrometry Core Facility at the Institute for Research in Biomedicine (IRB Barcelona) as follows: samples were in-gel digested with trypsin at the Proteomics Platform at the Barcelona Science Park. After the digestion, samples were dried in the speed-vac and resuspended in 20 μl of 1% formic acid for LC-MS/MS analysis. Digested peptides were diluted in 1% FA. Samples were loaded into a 180 μm × 2 cm C18 Symmetry trap column (Waters Corp., Milford, MA) at a flow rate of 15 μl/min using a nanoAcquity Ultra Performance LCTM chromatographic system (Waters Corp.). Peptides were separated using a C18 analytical column with a 60 min run, comprising three consecutive steps with linear gradients from 1% to 35% B in 60 min, from 35%delete to 50% B in 5 min, and from 50% to 85% B in 3 min, followed by isocratic elution at 85% B in 10 min and stabilization to initial conditions (A = 0.1% FA in water, B = 0.1% FA in CH~3~CN). The column outlet was directly connected to an Advion TriVersa NanoMate (Advion, Ithaca, NY) fitted on an LTQ-FT Ultra mass spectrometer (Thermo Fisher Scientific). The mass spectrometer was operated in a data-dependent acquisition (DDA) mode. Up to six of the most intense ions per scan were fragmented and detected in the linear ion trap. Target ions already selected for MS/MS were dynamically excluded for 30 s. Spray voltage in the NanoMate source was set to 1.70 kV. The spectrometer was working in positive polarity mode and singly charge state precursors were rejected for fragmentation. For data analysis, a database search was performed with Proteome Discoverer software v1.3 (Thermo Fisher Scientific) using the Sequest search engine and SwissProt database (Xenopodinae, release 2013_06 and the common Repository of Adventitious Proteins, cRAP database). Searches were run against targeted and decoy databases to determine the false discovery rate (FDR). Search parameters included trypsin enzyme specificity, allowing for two missed cleavage sites, carbamidomethyl in cysteine as static modification and methionine oxidation, and phosphorylation at serine, threonine and tyrosine as dynamic modifications. Peptide mass tolerance was 10 ppm and the MS/MS tolerance was 0.8 Da. Peptides with a q-value lower than 0.1 and a FDR \< 1% were considered as positive identifications with a high confidence level.

Two-dimensional phosphopeptide maps {#s4-9}
-----------------------------------

xCPEB4 fragments were phosphorylated *in vitro* as described previously. When using oocyte extracts as the source of kinases, xCPEB4 was re-purified from the kinase reaction with Ni^2+^-NTA agarose (Qiagen). Samples were in-gel digested with sequencing grade modified trypsin (fragment 3) or a combination of trypsin and chymotrypsin (fragment 1 and 2) (both enzymes from Promega). Phosphopeptides were extracted and loaded in glass-backed TLC plates (Sigma-Aldrich or C.B.S. Scientific, Del Mar, CA). The first dimension thin-layer electrophoresis was carried out in a Hunter Thin Layer Peptide Mapping Electrophoresis System (C.B.S. Scientific) with pH 1.9 buffer (2.2% formic acid/7.8% glacial acetic acid in deionized water) at 1000V for 45 min (Sigma-Aldrich TLC plates) or 35 min (C.B.S. Scientific TLC plates). The second dimension thin-layer chromatography was run in Phospho-chromatography buffer (37.5% 1-butanol/25% pyridine/7.5% glacial acetic acid in deionized water). Plates were dried, exposed, and developed with phosphorimager ([@bib29]).

Competition experiments {#s4-10}
-----------------------

Competition experiments were performed as described previously ([@bib1]) with 0.146 pmols of *in vitro* transcribed and polyadenylated RNA encoding for HA-CPEB4 (WT or mutants). 0% competition was assigned to WT HA-CPEB4, while 100% competition was assigned to the HA-CPEB4-12A mutant. The percentage of competition of the other conditions was normalized on the basis of these values.

Anti-sense oligonucleotide and phenotypic rescue experiment {#s4-11}
-----------------------------------------------------------

Rescue experiments were performed as described previously ([@bib20]) with some modifications. In order to ablate xCPEB4 expression, 116 ng of 20AS oligonucleotide (5'-GCAATGGGTTGCTCAGTTCCA-3') targeting xCPEB4 3'UTR were injected in stage VI oocytes. As a control, we used 23S oligonucleotide (5'-CTTTGCAAGCATCCAAATAAG-3'). After O/N incubation at 18°C, 2.43 fmols of *in vitro* transcribed HA-xCPEB4 + 3'UTR (WT or phospho-mutants) were injected. Oocytes were incubated for 1 hr at RT and maturation was induced. Oocytes were collected 2.5 hr after GVBD, fixed, and stained with Hoechst (20 μg/l). Images were obtained with a Nikon TE200 microscope (x 100 magnification, Olympus DP72 camera).

Poly(A) tail assay {#s4-12}
------------------

RNA-ligation-coupled RT-PCR was performed as described previously with some modifications ([@bib11]; [@bib20]). 4 μg of total oocyte RNA were ligated to 0.5 μg of SP2 anchor primer (5'-P-GGTCACCTCTGATCTGGAAGCGAC-NH2-3') in a 10 μl reaction using T4 RNA ligase (New England Biolabs), following manufacturer's indications. RNA-ligation reaction was reverse transcribed with the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific), using 0.5 μg ASP2T antisense primer (5'- GTCGCTTCCAGATCAGAGGTGACCTTTTT-3') in a reaction volume of 50 μl. 0.6 μl of cDNA were used to do gene-specific PCR reactions (30 μl) with BioTaq Polymerase (Bioline, London, UK). The primer used for Emi2 PCR was 5'- GTATATACATTCATTTGTTCAATGT TGCC-3'. 7.5 μl of PCR were loaded in 1.7% agarose gel and a Southern Blot was performed, using as probe the radiolabeled primer 5'- TGCAGCTAAATAGGTAGACGACATAC-3'.

Immunoprecipitation from *X. laevis* oocytes {#s4-13}
--------------------------------------------

Stage VI oocytes were injected with 4.9 fmols of *in vitro* transcribed HA-xCPEB4 + 3'UTR (wild type or phospho-mutants) and collected at indicated times. Oocytes were homogenized with 10 μl/oocyte of IP lysis buffer (20 mM Tris-HCl pH 8, 1 mM EDTA, 0.5% NP-40, 1 mM MgCl~2~ and 100 mM NaCl) supplemented with H1 kinase buffer and EDTA-free protease inhibitors (Sigma-Aldrich). 280 μl of oocyte extract was pre-cleared with 25 μl of Dynabeads protein G (Invitrogen) and then incubated for 2 hr at 4°C with anti-HA antibody covalently cross-linked to Dynabeads protein G. Immunoprecipitates were washed six times with IP lysis buffer and eluted with Laemmli sample buffer by heating at 65°C for 20 min. Eluates were resolved in SDS-PAGE, and analysed by Western blotting, silver staining (Pierce Silver Stain for Mass Spectrometry, Thermo Fisher Scientific) or colloidal blue staining (Invitrogen). Mass spectrometry analysis was performed at the Mass Spectrometry Core Facility at IRB Barcelona, as described previously.

Cell culture, DNA transfection and cell synchronization {#s4-14}
-------------------------------------------------------

U2OS cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. When specified, cells were transfected at 80% confluence with 2.5 μg of pPEU16_xCPEB4 plasmid (full length or fragments; WT or phospho-mutants) using Lipofectamine LTX and PLUS Reagent (Life Technologies, Carlsbad, CA). For selection of M-phase cells, cells were synchronized at M-phase with Nocodazole (Sigma-Aldrich) at 100 ng/μl for 16 hr. Alternatively, cells were synchronized at the G2/M with the Cdk1 inhibitor RO-3306 (Merck Millipore) at 9 μM for 21 hr, released and collected 45 min after release (M-phase). In both cases, mitotic cells were collected by mitotic shake-off.

GFP-xCPEB4 distribution in U2OS cells {#s4-15}
-------------------------------------

Cells were plated and transfected on glass coverslips. 24 hr after transfection, cells were fixed with 1X PBS/4% formaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 10 min at RT, permeabilized with 1X PBS/0.2% Triton X-100 for 5 min at RT and mounted with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). Image acquisition was performed with a High Throughput Automated Wide-field Olympus IX81 Microscope (Olympus Life Science Europe, Waltham, MA) and a 20x objective. ScanR Acquisition software was used to automatically take 64 images per condition. 100 cells from each condition were analysed with Fiji software.

Fluorescence recovery after photobleaching (FRAP) {#s4-16}
-------------------------------------------------

Fluorescence Recovery After Photobleaching was preformed on a Spinning Disk Microscope (Andor Revolution xD, Andor, Belfast, Ireland) equipped with a FRAPPA module allowing fast switching between FRAP and imaging with the same 488 nm laser set at about 5--10 mW. Typical frame rate achieved was 15 images per second with an exposure time of 50 ms on an EMCCD camera (Andor). Image sequences were analysed with Fiji (ImageJ) to register and quantify intensity. Exported data was analysed in Igor (Wavemetrics) with a custom FRAP procedure (open source code version by kota miura. (2016). FrapCalc: First github release. Zenodo. 10.5281/zenodo.46873; <https://zenodo.org/record/46873>). FRAP curves were fitted with a single exponential model and half time and mobile fractions were extracted.

Immunofluorescence {#s4-17}
------------------

Cells were plated, transfected, fixed and permeabilized as described. Blocking was performed with 1X PBS/10% FBS/0.03% Triton X-100 for 1 hr at RT. Incubation with primary antibodies was done O/N at 4°C, followed by three 5 min washes with 1X PBS. Finally, samples were incubated with the corresponding secondary antibodies for 1 hr at RT, washed three times with 1X PBS and mounted with VECTASHIELD Mounting Medium with DAPI (Vector Laboratories). Images were obtained on an inverted Leica TCS SP5 confocal microscope with a 63x/1.40--0.60 Oil objective.

Sucrose gradients {#s4-18}
-----------------

U2OS cells were cultured and synchronized at M-phase when specified. Cells were washed with 1X PBS and crosslinked with 0.5% formaldehyde in 1X PBS for 5 min at RT. Crosslinking was stopped with 0.25 M glycine during 4 min. After, cells were washed twice with cold 1X PBS, frozen at −80°C for 10 min and lysed with RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM MgCl~2~, 1 % NP-40, 0.5% sodium deoxicholate, 0.1% SDS, 1 mM EDTA) supplemented with H1K buffer 1X (80 mM sodium β-glycerolphosphate pH 7.4, 20 mM EGTA, 15 mM MgCl~2~, 0.5 mM Na~3~VO4), EDTA-free protease inhibitor cocktail (Sigma-Aldrich), phosphatase inhibitor cocktail 3 (Sigma-Aldrich) and RiboLock RNAse Inhibitor (Thermo Fisher Scientific). Cell lysate was sonicated 15 min at low intensity and centrifuged 30 min at 12000 g and 4°C. The supernatant was recovered. 200 μg of cellular extract were loaded in 5%--40% sucrose gradient and centrifuged at 50000 rpm with MLS-50 rotor (Beckman Coulter, Brea, CA) for 4 hr at 4°C. Fractions of 200 μl were manually obtained from the top to the bottom of the tube. Each fraction was subjected to protein precipitation with trichloroacetic acid, resolved in SDS-PAGE and analysed by Western blotting.

Immunoprecipitation from U2OS cell extracts {#s4-19}
-------------------------------------------

Cellular extracts were prepared as described in the previous section. Cellular extract (800 μg) was pre-cleared with 20 μl of Dynabeads protein A (Invitrogen) for 30 min at 4°C. After, it was incubated with 10 μg of anti-hCPEB4 antibody covalently cross-linked to 50 μl of Dynabeads protein A, for 4 hr at 4°C. Immunoprecipitates were washed five times with RIPA buffer, eluted with Laemmli sample buffer by heating at 65°C for 20 min, resolved in SDS-PAGE and analysed by Western blotting.

RNA-immunoprecipitation RT-qPCR from sucrose gradients {#s4-20}
------------------------------------------------------

Fractions obtained from sucrose gradients were pooled as DENSE FRACTIONS (17+19+21) or LIGHT FRACTIONS (5+7+9) and diluted 1:1 in RIPA buffer supplemented with EDTA-free protease inhibitor cocktail (Sigma-Aldrich), phosphatase inhibitor cocktail 3 (Sigma-Aldrich) and RiboLock RNAse Inhibitor (Thermo Fisher Scientific). The resulting extract was pre-cleared with 20 μl of Dynabeads protein A (Invitrogen) for 30 min at 4°C. After, it was incubated with 10 μg of anti-hCPEB4 antibody covalently cross-linked to 50 μl of Dynabeads protein A, for 4 hr at 4°C. Immunoprecipitates were washed five times with RIPA buffer. 2/3 of the immunoprecipitate were digested with Proteinase K during 1 hr at 65°C, and the RNA was isolated by phenol-chloroform extraction. All the RNA was used for reverse transcription with random hexamers and Oligo d(T)~20~, using SuperScript IV Reverse Transcriptase (Invitrogen) and following manufacturer's instructions. The resulting cDNA was used for gene-specific qPCR, using the following primers:

*Cdc20* FW: 5'- GCAAGCTCTGGTGACATCCT-3'

*Cdc20* RV: 5'- ACATGGTGTTCTGCTACCCG-3'

*Spop* FW: 5'-GAGGGGAAGAGACTGCATTG-3'

*Spop* RV: 5'-GCAGCAACAGGGTTTTCATT-3'

*Mnt* FW: 5'-TAGTGGCTGTTCATGCTCCA-3'

*Mnt* RV: 5'-TCTCAGGTTTCAGTGCAGGGTT-3'

*Gapdh* FW: 5'- CGCTCTCTGCTCCTCCTGTT-3'

*Gapdh* RV: 5'- CCATGGTGTCTGAGCGATGT-3'

Dynamic light scattering (DLS) {#s4-21}
------------------------------

Purified xCPEB4 N-terminal domain, in 25 mM Tris-HCl pH 8, 100 mM NaCl, 5% glycerol, 5 mM MgCl~2~ and 2 M urea buffer, was diluted in a non-containing urea buffer to a final protein concentration of 0.5 mg/ml and 0.2 M urea (other buffer components were kept at the same concentration). Samples were incubated at 4°C for 30 min before DLS analysis. For phosphorylation assays, proteins were diluted in NEBuffer for PK (New England Biolabs) containing 200 μM ATP, incubated on ice for 30 min and immediately phosphorylated with Cdk1/cyclin B (20 ng / μg xCPEB4 N-terminal domain) and ERK2 (10 U / μg xCPEB4 N-terminal domain) at 30°C for 30 min. Kinase reactions were stopped with 20 mM EDTA and kept at 4°C. 100 μl of sample were analysed by DLS with a Zetasizer Nano-S instrument (Malvern, Malvern, UK) at 25°C. Three measurements were obtained for each condition. Three independent experiments were performed.

Transmission electron microscopy (TEM) {#s4-22}
--------------------------------------

Sample preparation was performed as described for DLS. 6 μl of sample were deposited on carbon film only grids (CF200-CU, Electron Microscopy Sciences) and stained with uranyl formate for 1 min. EM was performed with a Tecnai Spirit microscope (EM) (FEI, Eindhoven, The Netherlands), equipped with a LaB6 cathode. Images were acquired at 120 kV and RT with a 1376 × 1024 pixel CCD camera (FEI, Eindhoven, The Netherlands).

*In vitro* xCPEB4 liquid-like droplets RNA-binding assay {#s4-23}
--------------------------------------------------------

4 μl of purified xCPEB4, full-length or N-terminal domain, at 2 mg/ml and 6 M urea were diluted with a urea-free buffer to a final volume of 12 μl in the presence of 3 μg of radiolabelled B1 or B1-123 RNA probe and 20 μg of tRNA. Samples were incubated 15 min at RT. After, proteins were diluted to a final volume of 100 μl in NEBuffer for PK (New England Biolabs) containing 200 μM ATP, incubated 30 min at 4°C and, when specified, phosphorylated with 500 U ERK2 and 1 μg Cdk1/cyclin B for 30 min at 30°C. Following phosphorylation, samples were loaded in Corning Costar Spin-X cellulose acetate 0.22 μm tube filters and centrifuged at 12,000 *g *for 1 min. Flow through was recovered and the filter column was washed with NEBuffer for PK. 4% of input and 20% of flow through were resolved in SDS-PAGE. Filters were exposed and developed with phosphorimager.
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###### xCPEB4 12A- or 12D-interacting proteins.

HA-xCPEB4 12A or 12D were immunoprecipitated, and the interacting proteins were analysed by mass spectrometry (relative to [Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). Only proteins with a fold enrichment \> 1.5 with respect to the control IP are shown. Two independent experiments were performed.

**DOI:** [http://dx.doi.org/10.7554/eLife.19298.026](10.7554/eLife.19298.026)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"CPEB4 is regulated during cell cycle by ERK2/Cdk1-mediated phosphorylation and its assembly into liquid-like droplets\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, one of whom, Nick Proudfoot (Reviewer \#1), is a member of our Board of Reviewing Editors and the evaluation has been overseen by Tony Hunter as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This study describes the discovery and role of multiple phosphorylations on the regulatory RNA binding protein CPEB4 in both *Xenopus* oocyte development and in a human cell line, U2OS. The study begins by showing that the N-terminal half of this protein (NTD) is subject to multiple phosphorylation events ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Both the sites of phosphorylation as well as the likely kinases involved (Erk2 and Cdk1) are identified by using specific kinase inhibitors together with biochemistry and mass spec analysis. The study goes on to show that phosphorylation of these specific residues are required for efficient polyadenylation activation. The final and arguably most important remaining parts of this study show that CPEB4 NTD when unphosphorylated coalesces into large structures/particles visualised as cytoplasmic bodies. These are detected by transfecting GFP-tagged CPEB4 constructs into human U2OS cells or as liquid droplets characterized by sucrose gradient fractionation and *in vitro* EM studies.

Overall, the reviewers find this study interesting and topical. However we have identified several points that need additional experimentation. Also reviewer 2 has provided a list of more detailed points that should also be addressed in the revision.

Essential revisions:

1\) It would be valuable to back up the kinase chemical inhibition experiments by specifically depleting Erk2 and Cdk1 to confirm their role in CPEB4 phosphorylation. Presumably this can be done using antisense RNAs -- successfully used in later experiments to deplete CPEB4.

2\) In these studies exogenously expressed xCPEB4 protein mutants (dominant negative) were employed to compete with endogenous xCPEB4 in activating synthetic substrate RNA polyadenylation. These data provide evidence that xCPEB4 NTD phosphorylation is required for polyadenylation. Even though this competition assay has been employed in previous studies, it still appears to be a somewhat indirect approach to measure polyadenylation. It would be desirable to test the critical xCPEB4 protein mutants in oocytes depleted for endogenous xCPEB4 so that a direct measurement of their effects on substrate RNA polyadenylation can be tested.

3\) A major issue is that it is assumed that the inactivation of the CPEB4 is due to the formation of liquid droplets that may sequester the mRNA targets. However, this conclusion has not been directly addressed. By definition the protein in liquid droplets is in equilibrium with the cytoplasmic soluble pool and therefore the reason why the protein is inactive could be indirect. For example, the protein fails to recruit some protein partner or cofactor. Liquid droplet formation may be a consequence not the cause of the inactivity. Also, it is not clear what fraction of the mRNA pool is sequestered in droplets and whether this can explain why the poly(A) tails are not extended. Therefore, this value and the proportion of the total CPEB4 population that is in the liquid droplet state need to be directly measured. In addition, are the interactions with known CPEB4 binding partners affected, as determined, for example, using co-immunoprecipitation with the human protein in human cells? This has been partially addressed for a subset of binding partners. But whether PARN or GLD2 colocalize together with CPEB4 in the droplets has not been investigated and should be. If the interactions are not affected as the authors claim, these proteins should also be present in the droplets and this raises the question of why the complexes are inactive. Such an outcome would need to be discussed in the paper.

10.7554/eLife.19298.028

Author response

*\[...\] Essential revisions:*

*1) It would be valuable to back up the kinase chemical inhibition experiments by specifically depleting Erk2 and Cdk1 to confirm their role in CPEB4 phosphorylation. Presumably this can be done using antisense RNAs -- successfully used in later experiments to deplete CPEB4.*

The identification of the kinases that phosphorylate CPEB4 is based in three evidences. As the reviewer points, each approach has its own limitations, but together we believe make a strong argument for the identity of the kinases. (i) The time course of xCPEB4 (FL and fragments) phosphorylation shows that xCPEB4 is not phosphorylated in Prophase I (PI) but only after metaphase I (MI), moreover one of the fragments follows the well-characterized, and unique in oocytes, profile of Cdk1. Based on the very numerous studies dealing with kinase-activities during meiosis, these profiles narrow down the suspected kinases to a very limited number. (ii) Then, we test these candidates with inhibitors. (iii) We phosphorylate recombinant xCPEB4 with purified/recombinant kinases and compare the resulting phosphopeptide maps with those obtained with phase-specific oocyte extracts.

Following the reviewers' suggestion, we have now added another approach to verify the identity of the kinases. However, mRNA-targeting (to deplete the encoded protein) has two relevant technical and conceptual limitations in this case. First, in *X. laevis* oocytes, this approach is only feasible for maternally encoded proteins (like xCPEB4). For proteins that are already present in PI-arrested oocytes (like ERK2 and Cdk1), targeting their mRNAs does no result in reduction of the proteins within the timeframe of the experiments. The second one, and this would apply also to mRNA-targeting in cell cultures, inhibition of ERK2 and Cdk1 in cells/oocytes will block the entry of the cell/oocyte into Metaphase. Because CPEB4 is only phosphorylated in Metaphase, the result of the experiment will be similar to the above-mentioned time-course. It will say that CPEB4 kinases are activated in metaphase but not whether CPEB4 is a direct or indirect target of ERK2 and Cdk1. This is the reason why, in the kinase-inhibitor experiments, first we obtain oocyte extracts synchronized for each meiotic-phase and then treat the extracts with the inhibitors. This approach, with the intrinsic limitations of the specificity of the inhibitors, points to a direct phosphorylation of CPEB4 by the targeted kinase(s).

To complement these approaches, we have now immunodepleted ERK2 and Cdk1 from oocyte extracts synchronized in metaphase II (New [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Cdk1 immunodepletion leads to a 21% reduction of xCPEB4 phosphorylation (note that Cdk1 is responsible for the phosphorylation of 5 out of the 12 identified phosphorylation sites). In the case of ERK2, which phosphorylates at least 7 residues on xCPEB4 NTD, its immunodepletion results in a 26% further reduction of xCPEB4 phosphorylation, even though ERK2 depletion was not complete. Although it is almost impossible to immunodeplete two kinases to get a near-complete abolishment of their activities, we have found a significant reduction, but not complete inhibition, of xCPEB4 phosphorylation.

*2) In these studies exogenously expressed xCPEB4 protein mutants (dominant negative) were employed to compete with endogenous xCPEB4 in activating synthetic substrate RNA polyadenylation. These data provide evidence that xCPEB4 NTD phosphorylation is required for polyadenylation. Even though this competition assay has been employed in previous studies, it still appears to be a somewhat indirect approach to measure polyadenylation. It would be desirable to test the critical xCPEB4 protein mutants in oocytes depleted for endogenous xCPEB4 so that a direct measurement of their effects on substrate RNA polyadenylation can be tested.*

That was the rationale behind the meiotic progression rescue experiment performed in the original submission ([Figure 3F](#fig3){ref-type="fig"}), where endogenous xCPEB4 was replaced by xCPEB4 phospho-mutants 12D or 12A and the progression into Metaphase II was assessed (as shown by the extrusion of the polar body and the assembly of the MII metaphase plate). Because transition from MI to MII and MII arrest requires xCPEB4-mediated polyadenylation of *Emi2* mRNA (Belloc 2008 and Igea 2010), this was an indirect measurement of xCPEB4 activity.

Now we have repeated the experiment, depleting endogenous xCPEB4, expressing xCPEB4 12D or 12A mutants and measuring directly endogenous *Emi2* mRNA polyadenylation (New [Figure 3G](#fig3){ref-type="fig"}). The result confirms the competition assay in polyadenylation of a reporter and the rescue of meiotic progression, showing that xCPEB4 12D, but not xCPEB4 12A, rescues *Emi2* mRNA polyadenylation.

*3) A major issue is that it is assumed that the inactivation of the CPEB4 is due to the formation of liquid droplets that may sequester the mRNA targets. However, this conclusion has not been directly addressed. By definition the protein in liquid droplets is in equilibrium with the cytoplasmic soluble pool and therefore the reason why the protein is inactive could be indirect. For example, the protein fails to recruit some protein partner or cofactor. Liquid droplet formation may be a consequence not the cause of the inactivity.*

We agree with the reviewers that the cause/consequence relationship between phase-separation and translational inhibition is a difficult issue to be addressed directly (just looking at the P-body literature, for many years, gives an idea of the complexity).

In the case of CPEB4-phosphorylation/phase-separation, we think that a causal effect is more probable based in our observations. Thus, CPEB4 12A is not active in cytoplasmic polyadenylation and mediates the assembly of liquid-like droplets (LLDs), whereas CPEB4 12D drives polyadenylation and translational activation and prevents LLDs. These observations are consistent with both models:

(i)"Consequence": CPEB4 12A assembles a repression complex, by recruiting specific cofactors, and then this complex is "stored" in LLDs.

\(ii\) "Cause": CPEB4 12A, bound to mRNAs, assembles LLDs, which in turn prevent the translational activation (i.e. polyadenylation and ribosomal recruitment).

However, the first model implies that CPEB4 12A should specifically recruit cofactors that mediate the translational repression. Proteomic analysis of the proteins bound to CPEB4 12A and 12D did not identify such cofactors. Moreover, this model would imply that the LLDs would only be generated after the repression complex has been assembled, through the recruitment of co-factors. But, not only the LLDs are generated in the absence of the RRMs required to assemble the repression complex, but also purified recombinant CPEB4 (or CPEB4 N-terminal IDRs) forms LLDs *in vitro*, regulated by phosphorylation, in the absence of co-factors. Thus, the formation of LLDs is an intrinsic property of CPEB4 IDRs and, when the RRMs are present, CPEB4 recruits mRNAs to these LLDs, sequestering the mRNA.

As the reviewer mentions, LLDs and soluble CPEB4 are in equilibrium, which is displaced toward the LLD state when CPEB4 is not phosphorylated, and even further when the LLDs contain mRNA (as shown by FRAP experiments). Thus, in an equilibrium between translation and repression, non-phosphorylated CPEB4 would favor the repression state.

We have included the core of these arguments in the revised version of the manuscript.

Also, it is not clear what fraction of the mRNA pool is sequestered in droplets and whether this can explain why the poly(A) tails are not extended. Therefore, this value and the proportion of the total CPEB4 population that is in the liquid droplet state need to be directly measured.

To address these points we have expanded the analyses of CPEB4 phase-separation in somatic cells, comparing asynchronous cells, where CPEB4 is mainly in LLDs, with M-phase arrested cells (please note that in an asynchronous population 5-8% of cells will be in mitosis). CPEB4 complexes from these two populations were resolved by sucrose gradient-centrifugation and the resulting fractions were analyzed for CPEB4 distribution and for CPEB4-associated mRNAs.

New [Figure 6C](#fig6){ref-type="fig"} shows the distribution of CPEB4 along the gradient (as % of total intensity). In asynchronous cells, 75% of CPEB4 is in LLD (dense fractions 15-23), while in M-phase 84% is in a monomeric state (light fractions 1-13).

New [Figure 7B](#fig7){ref-type="fig"} shows the association of CPEB4 (monomeric and LLD state) to its target mRNAs: *Cdc20*, *Spop* and *Mnt*. These three candidates were chosen because they are specifically polyadenylated and activated in mitosis and in a CPEB4 dependent manner (Novoa et al., 2010). Thence, RNA-immunoprecipitation from specific sucrose gradient fractions shows: (i) In asynchronous cells, where the majority of CPEB4 is in the LLD state, 63% of *Cdc20*, 92% of *Spop* and 78% of *Mnt* mRNAs bound to CPEB4 are bound by CPEB4 in the LLD state (dense fractions). (ii) In M-phase, when CPEB4 LLDs disassemble, 75% of *Cdc20*, 83% of *Spop* and 88% of *Mnt* mRNAs bound to CPEB4 are bound by monomeric CPEB4 (light fractions). These results show that both physical states of CPEB4 are equally able to bind target mRNAs. We conclude that when CPEB4 is not phosphorylated its target mRNAs are majorly bound by the LLDs, while upon phosphorylation these target mRNAs are bound by monomeric CPEB4. Together with the finding that CPEB4-LLDs do not contain ribosomes, these percentages are consistent with the translational repression and activation of the mRNAs encoding these three cell cycle regulators.

*In addition, are the interactions with known CPEB4 binding partners affected, as determined, for example, using co-immunoprecipitation with the human protein in human cells? This has been partially addressed for a subset of binding partners. But whether PARN or GLD2 colocalize together with CPEB4 in the droplets has not been investigated and should be. If the interactions are not affected as the authors claim, these proteins should also be present in the droplets and this raises the question of why the complexes are inactive. Such an outcome would need to be discussed in the paper.*

Please, note that there are no known "repression specific" co-factors for CPEB4. Identification of such repressor complex was the original aim of the CPEB4 12A IP followed by mass spectrometry, with the conclusion that no such co-factor was detected. Moreover, the association with the poly(A) polymerase GLD2 was unaffected by the phosphorylation state of CPEB4 in oocytes. These results drove us to explore if, unlike CPEB1, where the phosphorylation of a single site changes the identity of the associated proteins, for CPEB4 a change of its physical state itself and not a specific cofactor could be the cause of the regulation of its activity.

Now, we have further analyzed possible CPEB4 co-factors shared with CPEB1 repression/activation complexes. To this aim, we have performed CPEB4 co-IP in mammalian cells followed by western blot for known CPEB1 co-factors and we have checked the distribution of these co-factors along sucrose gradients. We found that both CPSF2 and Symplekin, which are distributed in both dense and light fractions of the gradients, are bound to CPEB4, without differences between the free and the LLD state (New [Figures 6B](#fig6){ref-type="fig"} and [7A](#fig7){ref-type="fig"}). The association with GLD2 in mammalian cells was difficult to address by co-IP (it co-migrates with the heavy chain of the antibodies used in the IP). Nevertheless, we show that GLD2 is present in both dense and light fractions of the gradients (New [Figure 6B](#fig6){ref-type="fig"}), which fits with the result obtained in oocytes where we show that GLD2 is equally associated with the 12A (LLD) and the 12D (monomeric) CPEB4 mutants. We failed to detect PARN in the co-IPs and, in fact, PARN is not present in the dense fractions of the gradient (New [Figure 6B](#fig6){ref-type="fig"}), suggesting that it does not co-localize with CPEB4 in the LLD. We did also look for the presence of ribosomes in the LLD (S6) and we found that there are no ribosomes associated with CPEB4 (New [Figure 7A](#fig7){ref-type="fig"}).

Altogether, we could not find any co-factor of CPEB4 associating differently depending on its phosphorylation/physical state. However, GLD2, Symplekin and CPSF are present in both CPEB1 repression/deadenylation and activation/polyadenylation complexes (Barnard 2004. Kim 2006). So it seems difficult to extract any functional conclusion from these associations. In conclusion, we believe that our data support the idea that it is the phosphorylation-regulated phase-separation itself, and not the differential binding to positive or negative co-factors, what defines the dual role of CPEB4 as a translational repressor or activator. We have included this argument in the manuscript.
